Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
grade F 0.41 3.80% 0.02
ALIM closed up 3.8 percent on Friday, September 13, 2019, on 1.16 times normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Up
See historical ALIM trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
20 DMA Resistance Bearish 3.80%
1,2,3 Retracement Bearish Bearish Swing Setup 3.80%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.80%
Pocket Pivot Bullish Swing Setup 3.80%
Wide Bands Range Expansion 3.80%

Older signals for ALIM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.
Medicine Chemistry Biopharmaceutical Diseases Organ Systems Disease Diabetes Age Related Macular Degeneration Blindness Fluid Dynamics Glucocorticoids Macular Edema Diabetic Retinopathy Diabetic Macular Edema Retina Pregnanes Alimera Sciences Diketones Retinal Vein Occlusion
Is ALIM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 1.21
52 Week Low 0.32
Average Volume 232,409
200-Day Moving Average 0.8774
50-Day Moving Average 0.6104
20-Day Moving Average 0.4188
10-Day Moving Average 0.3734
Average True Range 0.0513
ADX 56.32
+DI 14.2479
-DI 26.4067
Chandelier Exit (Long, 3 ATRs ) 0.4161
Chandelier Exit (Short, 3 ATRs ) 0.4739
Upper Bollinger Band 0.5231
Lower Bollinger Band 0.3145
Percent B (%b) 0.46
BandWidth 49.808978
MACD Line -0.0661
MACD Signal Line -0.0769
MACD Histogram 0.0108
Fundamentals Value
Market Cap 28.31 Million
Num Shares 69 Million
EPS -0.39
Price-to-Earnings (P/E) Ratio -1.05
Price-to-Sales 2.38
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.48
Resistance 3 (R3) 0.48 0.46 0.47
Resistance 2 (R2) 0.46 0.44 0.46 0.47
Resistance 1 (R1) 0.43 0.43 0.42 0.43 0.46
Pivot Point 0.41 0.41 0.40 0.41 0.41
Support 1 (S1) 0.38 0.39 0.37 0.39 0.36
Support 2 (S2) 0.36 0.38 0.36 0.35
Support 3 (S3) 0.34 0.36 0.35
Support 4 (S4) 0.34